How much funding has Ardelyx raised?

Ardelyx has raised $140.0M in total funding, most recently a Private Equity round.

Who are Ardelyx's investors?

Ardelyx's investors include NEA, CMEA, Amgen.

Where is Ardelyx headquartered?

Ardelyx is headquartered in Fremont, California, United States.

What industry is Ardelyx in?

Ardelyx operates in Biopharmaceutical, Healthcare, Therapeutics.

Ardelyx

IPO

Public · Fremont, United States · Founded 2007 · $140.0M raised

Biopharmaceutical

Healthcare

Therapeutics

Headquarters: Fremont, California
Employees: 201–500
Founded: 2007
Business Model: B2B
Website: ardelyx.com

Total Funding: $140.0M
Last Round: $110.0M Private EquityJul 2016
Rounds: 2
Type: Public

About

Ardelyx (Nasdaq: ARDX) is a biopharmaceutical company dedicated to developing first-in-class medicines that improve the lives of people living with kidney disease and gastrointestinal conditions. The company's lead approved product, XPHOZAH (tenapanor), is an FDA-approved treatment for hyperphosphatemia in adults with chronic kidney disease on dialysis.

Summary

Ardelyx is a Biopharmaceutical company based in Fremont, United States, founded in 2007. It has raised $140.0M in total across 2 rounds, most recently a $110.0M Private Equity round in Jul 2016. Investors include NEA, CMEA and Amgen.

LinkedIn X (Twitter)